Pharmacological characterization of adenosine A1 receptors and its functional role in brown trout (Salmo trutta) brain.
The adenosine receptor agonist N(6)-cyclohexyl[(3)H]adenosine ([(3)H]CHA) was used to identify and pharmacologically characterize adenosine A1 receptors in brown trout (Salmo trutta) brain. In membranes prepared from trout whole brain, the A1 receptor agonist [(3)H]CHA bound saturably, reversibly and with high affinity (K(d)=0. 69+/-0.04 nM; B(max)=0.624+/-0.012 pmol/mg protein) to a single class of binding sites. In equilibrium competition experiments, the adenosine agonists and antagonists all displaced [(3)H]CHA from high-affinity binding sites with the rank order of potency characteristic for an adenosine A1 receptors. A1 receptor density appeared not age-related (from 3 months until 4 years), and was similar in different brain areas. The specific binding was inhibited by guanosine 5'-triphosphate (IC(50)=0.778+/-0.067 microM). GTP (5 microM) induced a low affinity state of A1 receptors. In superfused trout cerebral synaptosomes, 30 mM K(+) stimulated the release of glutamate in a calcium dependent manner. Glutamate-evoked release was dose-dependently reduced by CHA, and the inhibition was reversed by the A1 antagonist 8-cyclopentyltheophylline (CPT). In the same synaptosomal preparation, 30 mM K(+) as well as 1 mM glutamate stimulated the release of adenosine in a Ca(2+)-independent manner and tetrodotoxin insensitive. These findings show that in trout brain adenosine A1 receptors are present which are involved in the modulation of glutamate transmitter release. Moreover, the stimulation of adenosine release by K(+) depolarisation or glutamate support the hypothesis that, as in mammalian brain, a cross-talk between adenosine and glutamate systems exists also in trout brain.
Poli
A
A
Department of Biology, University of Bologna, Via Selmi 3, 40126, Bologna, Italy. a.poli@alma.unibo.it
Lucchi
R
R
Notari
S
S
Zampacavallo
G
G
Gandolfi
O
O
Traversa
U
U
D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000502:physiology*; D002462:Cell Membrane / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D006153:Guanosine Diphosphate / Q000494:pharmacology; D007700:Kinetics; D018696:Neuroprotective Agents / Q000494:pharmacology; D011869:Radioligand Assay; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000378:metabolism*; D013574:Synaptosomes / Q000502:physiology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D014316:Tritium; D014337:Trout; D014970:Xanthines / Q000494:pharmacology
D018696:Neuroprotective Agents; D018047:Receptors, Purinergic P1; D014970:Xanthines; D014316:Tritium; D006153:Guanosine Diphosphate; C047235:N-(1-methyl-2-phenylethyl)adenosine; D019830:Adenosine-5'-(N-ethylcarboxamide); C027513:N(6)-cyclohexyladenosine; D018698:Glutamic Acid; C051360:1,3-dipropyl-8-cyclopentylxanthine; D013806:Theophylline; D000241:Adenosine